Cost-effectiveness Study of Celecoxib for Osteoarthritis in China / 中国药房
China Pharmacy
;
(12): 586-590, 2017.
Artigo
em Chinês
| WPRIM
| ID: wpr-673048
ABSTRACT
OBJECTIVE:
To evaluate cost-effectiveness of celecoxib for osteoarthritis(OA)in China.METHODS:
OA cost-ef-fectiveness analysis model developed by National Institute for Health and Clinical Excellence(NICE)was adopted using celecoxib, diclofenac+PPIs as control. Related risk Zof adverse event was from CONDOR trials.The effectiveness was measured by QALY. Costs and QALYs were discounted annually at 4.76%.RESULTS:
Celecoxib had a cost of $3 591 and 8.826 QALYs while diclofe-nac+PPIs had a cost of $3 674 and 8.830 QALYs. The incremental costs and QALYs of celecoxib to diclofenac+PPIs were -$83 and -0.004 QALYs,respectively. The incremental cost-effectiveness ratio(ICER)for diclofenac+PPIs to celecoxib was$23 258/QALY. The results of single factor sensitivity analysis and probability sensitivity analysis showed that drug cost was driving factor of IC-ER,and the results of two therapy plans were similar.CONCLUSIONS:
Celecoxib is a less costly alternative than diclofenac+PPIs. The difference in QALYs between celecoxib and diclofenac+PPIs is extremely small,so celecoxib is likely to be cost-effec-tive for OA patients.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Tipo de estudo:
Avaliação Econômica em Saúde
/
Estudo prognóstico
Idioma:
Chinês
Revista:
China Pharmacy
Ano de publicação:
2017
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS